Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00373711
Status:
WITHDRAWN
Last Update Posted:
2022-06-21
First Post:
2006-09-06
Brief Title:
Comparison of I-124 PETCT F-18 FDG PETCT I-123 Whole Body Scintigraphy for Recurrent Thyroid CA
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Comparison of I-124 PETCT F-18 FDG PETCT and I-123 Whole Body Scintigraphy for Recurrent Thyroid Cancer Detection
Status:
WITHDRAWN
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Abandoned
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The management of thyroid cancer patients with suspicion of recurrent disease based on risingdetectable levels of thyroglobulin Tg involves imaging with iodine-123 whole body scintigraphy I-123 WBS and F-18 FDG PETCT However the disease is not always detected The use of another iodine isotope I-124 with positron emitting characteristics for PETCT may allow better identification of recurrent disease thus allowing for more patients to be treated with I-131 as a curative attempt
Detailed Description:
The management of thyroid cancer patients with suspicion of recurrent disease based on risingdetectable levels of thyroglobulin Tg involves imaging with iodine-123 whole body scintigraphy I-123 WBS and F-18 FDG PETCT However the disease is not always detected The use of another iodine isotope I-124 with positron emitting characteristics for PETCT may allow better identification of recurrent disease thus allowing for more patients to be treated with I-131 as a curative attempt
Conducting this study we hope to find whether I-124 PETCT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PETCT
Conducting this study we hope to find whether I-124 PETCT allows for detection of more lesions in patients with suspected recurrent thyroid cancer than the current standard of care represented by I-123 WBS and F-18 FDG PETCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| END0003 | OTHER | Stanford University | None |
| 97454 | OTHER | None | None |